Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company focused on cancer drug development, with news flow that reflects both its scientific programs and corporate strategy. Company announcements emphasize its lead compound LB-100, a first-in-class PP2A inhibitor, and its efforts to develop and commercialize cancer therapies targeting solid tumors with unmet medical needs.
News about Lixte often highlights clinical trial progress for LB-100, including proof-of-concept studies in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Releases describe collaborations with major institutions such as The University of Texas MD Anderson Cancer Center and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, as well as partnerships with large pharmaceutical companies supplying immunotherapies for combination studies.
Investors following LIXT can also expect updates on strategic transactions and platform expansion. Recent news includes the acquisition of Liora Technologies Europe Ltd., which holds the LiGHT System, an electronically controlled proton therapy platform. This transaction marks Lixte’s entry into the radiotherapy segment of cancer care and is presented as a complement to its LB-100 program.
In addition, Lixte issues releases on capital raises, such as registered direct offerings and private placements, as well as governance and proxy matters described in its definitive proxy statement. For investors and observers, the LIXT news stream provides insight into how the company is advancing LB-100, building a multi-asset oncology platform, managing its capital structure, and executing on its stated mission in oncology.
WallachBeth Capital has successfully completed a $4.19 million Registered Direct Offering for Lixte Biotechnology Holdings (LIXT). A total of 1,133,102 shares of common stock were sold at $3.70 per share. The net proceeds will support working capital and further development of the lead clinical compound LB-100.
The offering was made under a previously filed shelf registration statement. The company is focused on innovative cancer treatment solutions, with LB-100 currently undergoing clinical trials.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced the completion of a registered direct offering, raising approximately $4.19 million through the sale of 1,133,102 shares of common stock at $3.70 per share. The funds will be allocated for working capital and further development of its lead clinical compound, LB-100. WestPark Capital, Inc. and WallachBeth Capital, LLC served as co-placement agents for this transaction.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced a direct offering of 1,133,102 shares of common stock at $3.70 per share, expected to generate approximately $4.19 million in gross proceeds. The funds will support working capital and the development of its lead compound, LB-100, which targets cancer treatment. The transaction is facilitated by WestPark Capital, Inc. and WallachBeth Capital, LLC, with the offering closing on or about March 2, 2021, pending customary conditions. The offering is conducted under a previously effective shelf registration statement.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO John S. Kovach will present the company's first-in-class compound, LB-100, which targets cancer treatment by enhancing the efficacy of standard therapies while minimizing toxicity. LB-100 is currently undergoing clinical studies across four cancer indications: Myelodysplastic Syndromes, Advanced Soft Tissue Sarcoma, Small Cell Lung Cancer, and Glioblastoma Multiforme. A webcast of the presentation will be available on the company's website.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced an agreement to conduct a Phase 1b clinical trial with City of Hope, focusing on the combination of its protein phosphatase inhibitor, LB-100, with a standard chemotherapy regimen for extensive stage disease small cell lung cancer (ED-SCLC). The trial aims to assess LB-100’s safety and therapeutic activity when combined with carboplatin, etoposide, and atezolizumab. LB-100 has shown promise in animal models by enhancing chemotherapy's antitumor effects without added toxicity.
On December 1, 2020, WallachBeth Capital announced the completion of a joint underwritten public offering for Lixte Biotechnology Holdings, Inc. (LIXT). The offering involved 1,200,000 shares priced at $4.75 each, generating gross proceeds of $5.7 million. Each unit comprises one share of common stock and one warrant with an exercise price of $5.70. The option for underwriters to purchase an additional 180,000 shares exists. Trading for these securities commenced on November 25, 2020, and this offering is filed under an effective SEC registration statement.
Lixte Biotechnology Holdings has completed a public offering of 1,200,000 units at a price of $4.75 per unit, totaling $5.7 million in gross proceeds. Each unit comprises one share of common stock and one warrant at an exercise price of $5.70. The offering, which closed on December 1, 2020, included an option for underwriters to purchase an additional 180,000 shares and/or warrants.
The securities began trading separately on the Nasdaq Capital Market on November 25, 2020.
Lixte Biotechnology Holdings, Inc. has successfully closed a follow-on offering, selling 1,200,000 units at $5,700,000 in total gross proceeds. Each unit comprises one share of common stock and one warrant. The offering, managed by WestPark Capital, Inc., is part of an effective registration statement filed with the SEC. The company, trading on Nasdaq under the symbols LIXT and LIXTW, focuses on innovative drug discovery targeting enzyme-related diseases, with a pipeline aimed at both cancer and other serious health conditions.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced a public offering of 1,200,000 units priced at $4.75 per unit, each consisting of one share of common stock and one warrant. The warrants are exercisable at $5.70, expiring in five years. The offering, following a reverse stock split of 1-for-6, aims to raise approximately $5.7 million for clinical trials, patent extensions, and general corporate purposes. The offering is expected to close around November 30, 2020, with underwriters granted an option for an additional 180,000 shares or warrants.